Google Verily and Stanford University plan to conduct baseline trials
Recently, Google's Verily announced that it will cooperate with Stanford and Duke University to start a four-year, recruitment of 10,000 volunteers for health information collection and tracking experiments. This baseline project (Baseline Project) will begin to test a variety of blood, body fluids, and feces indicators and genetic information for volunteers. The volunteers will follow the test five times in four years. Participants also wear a watch that monitors heart function and a tracking device that detects sleep to capture this information in real time. The trial is estimated to cost at least $300 million, and Singapore's Temasek Group will support $800 million. Drug source analysis Verily has previously worked with a number of major pharmaceutical companies to develop a variety of health products with sci-fi colors, from contact lenses for detecting blood sugar to nanometer three-degree instruments for comprehensive examination of diseases (famous science fiction TV show "Star Trek" ), last year and Glaxo cooperation development of electronic drugs (using pulsed waves to regulate biological processes). These products are facing significant barriers to conversion and there are currently no products on the market. Verily said today that the company has matured through the illusion of childhood, this time to do something that can affect the diagnosis and treatment of daily diseases. Participants who participated in this trial also had a higher risk of developing a higher risk, so this trial can define a baseline for health, and secondly, establish a basic biomarker and the association of various diseases. This is not the first long-term observation of the relationship between disease occurrence and lifestyle and biological indicators in a population. The Framingham trial, which established LDL and cardiovascular disease, began 70 years ago and is still ongoing. However, this baseline trial recruits a large number of patients, and more importantly, there are many observations and many indicators are tracked in real time. This requires a high-intensity information gathering, analysis, and processing system, and this is Google's strengths. The benefits that volunteers receive from this trial are limited, but they need to contribute a lot of privacy, so how many people can persist for four years is hard to predict. Many people are worried that this test will not find too many useful clues. This worry is not unfounded. Even the now confirmed associations of LDL/cardiovascular disease may be masked by noise due to the heterogeneity of participating volunteers, and there are certainly many false observations associated with the many indicators. Even if the association does exist, it cannot prove causality, and it cannot be proved that drug or lifestyle intervention will prevent or reverse the associated disease. When MRFIT was tried to control cholesterol intake and lower blood fat, the LDL was only down 6.5% after 7 years of follow-up, and there was no difference in mortality. HDL, powdered protein are two well-known examples of drug intervention failure. Monkeypox is a viral zoonosis (a virus transmitted tothose seen in the past in smallpox patients, typically-presents clinically with fever, rash and swollen lymphnodes and may lead to a range of medical complications.It is caused by the monkeypox virus which belongs totheorthopoxvirus genus of the Poxviridae family.Thereare two clades of monkeypox virus:the West Africanclade and the Congo Basin (Central African) clade.Theoname monkeypoxoriginates from the initial discovery ofthe virus in monkeys in a Danish laboratory in 1958.Thefirst human case was identified in a child in the Demo-cratic Republic of the Congo in 1970. Monkey Pox Test Kit,In vitro diagnostic tests,Rapid detection of monkeypox Jiangsu iiLO Biotechnology Co., Ltd. , https://www.iilogene.com